Bayer Swaps Legal Headaches for Trade Tensions as Ruveon Takes Center Stage

Bayer launches aggressive trade move via new subsidiary Ruveon, seeking duties on Chinese glyphosate imports. Stock surges 103% yearly but overbought signals and farmer opposition loom.

The script has flipped for Bayer's glyphosate business. Just days after a landmark Supreme Court ruling capped a devastating verdict at $1.25 million and the company created a dedicated US subsidiary to ringfence the herbicide, management launched an entirely new offensive — this time aimed at Beijing. On June 30, 2026, Bayer's newly formed unit Ruveon filed a petition with the US Department of Commerce and the International Trade Commission demanding anti-dumping duties on Chinese glyphosate imports. The move transforms the narrative from one of legal survival to aggressive trade protectionism, and the stock has responded with a surge that is both breathtaking and increasingly stretched.

Ruveon, headquartered in St. Louis, now controls every link in the glyphosate value chain for the US market — pricing, marketing and production. Its creation was made possible by a recent Supreme Court ruling that tightened warning-label obligations for glyphosate-based products, giving Bayer far more legal breathing room. The court victory alone erased a decade of uncertainty that had cost the group more than $10 billion in settlements and legal fees. Bayer's stock jumped as high as €53.86 on Friday, pushing the market capitalisation above €48 billion. The shares closed at €53.04, which still represents a gain of over 103% on a 12-month basis and roughly 40% since the start of the year.

Yet the tariff application reveals a different kind of vulnerability. CEO Bill Anderson had previously warned that cheap generic glyphosate from China could force Bayer to shutter US production entirely. By seeking duties, Bayer is attempting to protect its core agri-chemistry earnings but risks alienating the very farmers who buy its products. The American Corn Growers Association and the National Soybean Association have already voiced opposition, arguing that higher import costs will squeeze their margins. Bayer is essentially picking a fight with its biggest customer base while simultaneously celebrating a legal victory that was supposed to draw a line under the Monsanto legacy.

The market, however, is ignoring these new political headwinds. The relative strength index (RSI) for Bayer stock stands at 85.1, deep in overbought territory, and the annualised volatility is an eye-watering 63%. The share price has soared 43.56% above its 200-day moving average, a level that historically precedes sharp profit-taking. Chartists warn that the euphoria around Ruveon may be overdone, especially given that the subsidiary remains fully integrated inside Bayer for now — a true spin-off or IPO is still speculation.

The next critical milestone is the court hearing scheduled for August, where Bayer hopes to secure a comprehensive US settlement that would finally neutralise the bulk of its legal liabilities. If that hearing fails, the bullish case for Ruveon as a firewall collapses. If it succeeds, the stock could break through the €54 resistance level that has so far proved elusive. For the moment, the 50-day moving average near €39 provides a long-term safety net, but with the tariff application now in Washington's hands, Bayer faces a summer of dual uncertainty — one courtroom date and one trade case that could redefine the glyphosate market on both sides of the Pacific.